Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. (ALLR): 2 pipeline candidates · ~21 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.8 months
D/E 4.05 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Allarity Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$22.4M
Cash
$29.8M
Quarterly Burn
$4.5M
Runway
20.8 mo
Revenue
$25K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| stenoparib | Phase 2 |
| stenoparib (formerly E7449) | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$1.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 343,590 | $375K |
| renaissance technologies llc | 228,084 | $249K |
| geode capital management, llc | 190,393 | $208K |
| state street corp | 137,600 | $150K |
| vanguard fiduciary trust co | 74,913 | $82K |
| northern trust corp | 48,103 | $52K |
| xtx topco ltd | 28,967 | $32K |
| two sigma investments, lp | 27,492 | $30K |
| two sigma securities, llc | 12,334 | $13K |
| citigroup inc | 7,766 | $8K |
Showing top 10 of 13 institutional holders of Allarity Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Allarity Therapeutics, Inc.'s pipeline?
Allarity Therapeutics, Inc. (ALLR) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Allarity Therapeutics, Inc.'s lead drug candidate?
Allarity Therapeutics, Inc.'s most advanced tracked candidate is stenoparib (Phase 2) for Advanced, recurrent ovarian cancer; Platinum resistant or platinum ineligible ovarian cancer (PROC); Relapsed Small Cell Lung Cancer (SCLC).
What is Allarity Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Allarity Therapeutics, Inc. has approximately 20.8 months of cash runway.
What is Allarity Therapeutics, Inc.'s market capitalization?
Allarity Therapeutics, Inc.'s market capitalization is approximately $22.4M.
Who is the CEO of Allarity Therapeutics, Inc.?
Mr. Thomas H. Jensen is the chief executive officer of Allarity Therapeutics, Inc. (ALLR).
Get the full picture on Allarity Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.